Fujifilm to Acquire SonoSite for $995 Million
By MedImaging International staff writers Posted on 15 Dec 2011 |
Fujifilm Holdings Corp. (Tokyo, Japan), a diversified technology company focused on healthcare, highly functional materials, and document solutions, reported that it has entered into a definitive agreement with SonoSite, Inc. (Bothell, WA, USA), a developer of bedside and point-of-care ultrasound technology, pursuant to which Fujifilm will acquire SonoSite for about USD 995 million. The transaction was unanimously approved by the boards of directors of both companies.
Fujifilm, through a US subsidiary, will make an all-cash tender offer to purchase all outstanding shares of SonoSite common stock for USD 54 per share in cash. SonoSite’s board of directors will recommend that SonoSite’s shareholders tender their shares to Fujifilm pursuant to the offer. Upon completion of the acquisition, SonoSite will become a wholly owned subsidiary of Fujifilm, and will continue operations in Bothell, WA, USA. SonoSite will continue to be managed by its current leadership team, who will play a key role in driving the group’s future growth in the medical equipment sector, a key strategic mainstay of Fujifilm.
SonoSite, a manufacturer of point-of-care ultrasound products (POCU), specializes in the development of ultraportable devices that are used in more than 20 clinical specialties. The company also recently expanded into the preclinical research market with its newly acquired ultrahigh frequency micro-ultrasound technology. SonoSite’s systems were designed to improve healthcare delivery and efficiency by enabling physicians to deliver safer and less expensive care in hospitals and elsewhere.
SonoSite’s products are designed for applications where ultrasound has not typically been used, such as emergency medicine, surgery, critical care, internal medicine, musculoskeletal, and vascular access procedures, as well as for imaging in traditional applications, such as radiology, cardiology, vascular medicine, and obstetrics and gynecology.
This transaction will bring together the corresponding strengths of Fujifilm’s high-quality imaging technologies and SonoSite’s innovative point-of-care expertise and miniaturization capabilities, increasing the business’ leadership within the growing POCU sector. Specifically, the combined entity will be well positioned to (1) develop and produce industry-leading and price-competitive products for both point-of-care and traditional diagnostic markets, utilizing Fujifilm and SonoSite’s innovative manufacturing technologies. (2) Drive the geographic expansion of POCU devices by deploying a worldwide sales infrastructure and distribution channels on a reciprocal basis. (3) Drive the development and commercialization of next-generation compact, easy-to-use, and high-quality medical imaging devices resulting from the combination of Fujifilm’s proprietary imaging and laser technology and SonoSite’s sophisticated application-specific integrated circuit (ASIC) technology, innovative high-frequency ultrasound and transducer technology, and its photoacoustic imaging technology.
Utilizing their existing and future product range, Fujifilm and SonoSite, according to company spokespersons, will be able to capture the significant growth opportunities arising from new application areas in point-of-care ultrasound diagnosis and treatment.
Commenting on the transaction, President and CEO of Fujifilm, Shigetaka Komori, said, “We are delighted to be joining forces with SonoSite. This transaction significantly accelerates Fujifilm’s full-scale entry into the fast-growing hand-carried ultrasound equipment market and will position ultrasonography as a strategic pillar for the future growth of our medical systems business.
Beginning with the sales of X-ray films in 1936, Fujifilm gradually developed its business in the medical field. Since the release of the world’s first FCR [Fujifilm computed radiography] digital X-ray diagnostic imaging system in 1983, the company has continuously pursued one central goal: providing easy-to-interpret, high-quality images at the medical frontline. We are confident that, together with SonoSite, we will further enhance our technological expertise to develop medical imaging devices that contribute to the improvement of medical diagnostics and care quality for patients worldwide.”
SonoSite’s president and CEO, Kevin Goodwin, said, “We are pleased that this transaction gives our shareholders the opportunity to realize full value for their SonoSite shares. We are also very excited to be partnering with Fujifilm as it will enable us to significantly accelerate our international business and product development efforts, and respond to the fast-evolving needs of physicians around the world. We believe that the performance, size, ease of use, and cost-effectiveness of our products will drive further growth in existing ultrasound markets, and are opening new markets as they bring ultrasound visualization out of the imaging lab and to the point-of-care, whether at the patient’s bedside or the physician’s examination table.”
Fujifilm has effectively transformed its business structure for growth by expanding from traditional photographic film to other priority business fields. Positioning the medical systems and life sciences business as one of its major growth areas, Fujifilm is seeking to cover “prevention, diagnosis, and treatment” comprehensively as a total healthcare company.
SonoSite develops bedside and point-of-care ultrasound and is an industry leader in ultra-high-frequency micro-ultrasound technology and impedance cardiography equipment. The company is represented by 14 subsidiaries and a global distribution network in over 100 countries.
Fujifilm Holdings Corp. is the holding company of the Fujifilm Group having three operating companies (Fujifilm Corp., Fuji Xerox Co., Ltd. and Toyama Chemical Co., Ltd.) under its umbrella. The group’s priority business fields are: medical/life sciences such as medical equipment, pharmaceuticals, functional skin care cosmetics and nutritional supplements; graphic arts such as printing materials and equipment; documents such as office equipment/printing; optical devices such as camera phone lens units; highly functional materials such as liquid crystal display (LCD) materials; digital imaging such as digital cameras, digital printing, and Photobook.
Related Links:
Fujifilm
SonoSite
Fujifilm, through a US subsidiary, will make an all-cash tender offer to purchase all outstanding shares of SonoSite common stock for USD 54 per share in cash. SonoSite’s board of directors will recommend that SonoSite’s shareholders tender their shares to Fujifilm pursuant to the offer. Upon completion of the acquisition, SonoSite will become a wholly owned subsidiary of Fujifilm, and will continue operations in Bothell, WA, USA. SonoSite will continue to be managed by its current leadership team, who will play a key role in driving the group’s future growth in the medical equipment sector, a key strategic mainstay of Fujifilm.
SonoSite, a manufacturer of point-of-care ultrasound products (POCU), specializes in the development of ultraportable devices that are used in more than 20 clinical specialties. The company also recently expanded into the preclinical research market with its newly acquired ultrahigh frequency micro-ultrasound technology. SonoSite’s systems were designed to improve healthcare delivery and efficiency by enabling physicians to deliver safer and less expensive care in hospitals and elsewhere.
SonoSite’s products are designed for applications where ultrasound has not typically been used, such as emergency medicine, surgery, critical care, internal medicine, musculoskeletal, and vascular access procedures, as well as for imaging in traditional applications, such as radiology, cardiology, vascular medicine, and obstetrics and gynecology.
This transaction will bring together the corresponding strengths of Fujifilm’s high-quality imaging technologies and SonoSite’s innovative point-of-care expertise and miniaturization capabilities, increasing the business’ leadership within the growing POCU sector. Specifically, the combined entity will be well positioned to (1) develop and produce industry-leading and price-competitive products for both point-of-care and traditional diagnostic markets, utilizing Fujifilm and SonoSite’s innovative manufacturing technologies. (2) Drive the geographic expansion of POCU devices by deploying a worldwide sales infrastructure and distribution channels on a reciprocal basis. (3) Drive the development and commercialization of next-generation compact, easy-to-use, and high-quality medical imaging devices resulting from the combination of Fujifilm’s proprietary imaging and laser technology and SonoSite’s sophisticated application-specific integrated circuit (ASIC) technology, innovative high-frequency ultrasound and transducer technology, and its photoacoustic imaging technology.
Utilizing their existing and future product range, Fujifilm and SonoSite, according to company spokespersons, will be able to capture the significant growth opportunities arising from new application areas in point-of-care ultrasound diagnosis and treatment.
Commenting on the transaction, President and CEO of Fujifilm, Shigetaka Komori, said, “We are delighted to be joining forces with SonoSite. This transaction significantly accelerates Fujifilm’s full-scale entry into the fast-growing hand-carried ultrasound equipment market and will position ultrasonography as a strategic pillar for the future growth of our medical systems business.
Beginning with the sales of X-ray films in 1936, Fujifilm gradually developed its business in the medical field. Since the release of the world’s first FCR [Fujifilm computed radiography] digital X-ray diagnostic imaging system in 1983, the company has continuously pursued one central goal: providing easy-to-interpret, high-quality images at the medical frontline. We are confident that, together with SonoSite, we will further enhance our technological expertise to develop medical imaging devices that contribute to the improvement of medical diagnostics and care quality for patients worldwide.”
SonoSite’s president and CEO, Kevin Goodwin, said, “We are pleased that this transaction gives our shareholders the opportunity to realize full value for their SonoSite shares. We are also very excited to be partnering with Fujifilm as it will enable us to significantly accelerate our international business and product development efforts, and respond to the fast-evolving needs of physicians around the world. We believe that the performance, size, ease of use, and cost-effectiveness of our products will drive further growth in existing ultrasound markets, and are opening new markets as they bring ultrasound visualization out of the imaging lab and to the point-of-care, whether at the patient’s bedside or the physician’s examination table.”
Fujifilm has effectively transformed its business structure for growth by expanding from traditional photographic film to other priority business fields. Positioning the medical systems and life sciences business as one of its major growth areas, Fujifilm is seeking to cover “prevention, diagnosis, and treatment” comprehensively as a total healthcare company.
SonoSite develops bedside and point-of-care ultrasound and is an industry leader in ultra-high-frequency micro-ultrasound technology and impedance cardiography equipment. The company is represented by 14 subsidiaries and a global distribution network in over 100 countries.
Fujifilm Holdings Corp. is the holding company of the Fujifilm Group having three operating companies (Fujifilm Corp., Fuji Xerox Co., Ltd. and Toyama Chemical Co., Ltd.) under its umbrella. The group’s priority business fields are: medical/life sciences such as medical equipment, pharmaceuticals, functional skin care cosmetics and nutritional supplements; graphic arts such as printing materials and equipment; documents such as office equipment/printing; optical devices such as camera phone lens units; highly functional materials such as liquid crystal display (LCD) materials; digital imaging such as digital cameras, digital printing, and Photobook.
Related Links:
Fujifilm
SonoSite
Latest Industry News News
- GE HealthCare and NVIDIA Collaboration to Reimagine Diagnostic Imaging
- Patient-Specific 3D-Printed Phantoms Transform CT Imaging
- Siemens and Sectra Collaborate on Enhancing Radiology Workflows
- Bracco Diagnostics and ColoWatch Partner to Expand Availability CRC Screening Tests Using Virtual Colonoscopy
- Mindray Partners with TeleRay to Streamline Ultrasound Delivery
- Philips and Medtronic Partner on Stroke Care
- Siemens and Medtronic Enter into Global Partnership for Advancing Spine Care Imaging Technologies
- RSNA 2024 Technical Exhibits to Showcase Latest Advances in Radiology
- Bracco Collaborates with Arrayus on Microbubble-Assisted Focused Ultrasound Therapy for Pancreatic Cancer
- Innovative Collaboration to Enhance Ischemic Stroke Detection and Elevate Standards in Diagnostic Imaging
- RSNA 2024 Registration Opens
- Microsoft collaborates with Leading Academic Medical Systems to Advance AI in Medical Imaging
- GE HealthCare Acquires Intelligent Ultrasound Group’s Clinical Artificial Intelligence Business
- Bayer and Rad AI Collaborate on Expanding Use of Cutting Edge AI Radiology Operational Solutions
- Polish Med-Tech Company BrainScan to Expand Extensively into Foreign Markets
- Hologic Acquires UK-Based Breast Surgical Guidance Company Endomagnetics Ltd.
Channels
Radiography
view channel
AI Improves Early Detection of Interval Breast Cancers
Interval breast cancers, which occur between routine screenings, are easier to treat when detected earlier. Early detection can reduce the need for aggressive treatments and improve the chances of better outcomes.... Read more
World's Largest Class Single Crystal Diamond Radiation Detector Opens New Possibilities for Diagnostic Imaging
Diamonds possess ideal physical properties for radiation detection, such as exceptional thermal and chemical stability along with a quick response time. Made of carbon with an atomic number of six, diamonds... Read moreMRI
view channel
Cutting-Edge MRI Technology to Revolutionize Diagnosis of Common Heart Problem
Aortic stenosis is a common and potentially life-threatening heart condition. It occurs when the aortic valve, which regulates blood flow from the heart to the rest of the body, becomes stiff and narrow.... Read more
New MRI Technique Reveals True Heart Age to Prevent Attacks and Strokes
Heart disease remains one of the leading causes of death worldwide. Individuals with conditions such as diabetes or obesity often experience accelerated aging of their hearts, sometimes by decades.... Read more
AI Tool Predicts Relapse of Pediatric Brain Cancer from Brain MRI Scans
Many pediatric gliomas are treatable with surgery alone, but relapses can be catastrophic. Predicting which patients are at risk for recurrence remains challenging, leading to frequent follow-ups with... Read more
AI Tool Tracks Effectiveness of Multiple Sclerosis Treatments Using Brain MRI Scans
Multiple sclerosis (MS) is a condition in which the immune system attacks the brain and spinal cord, leading to impairments in movement, sensation, and cognition. Magnetic Resonance Imaging (MRI) markers... Read moreUltrasound
view channel.jpeg)
AI-Powered Lung Ultrasound Outperforms Human Experts in Tuberculosis Diagnosis
Despite global declines in tuberculosis (TB) rates in previous years, the incidence of TB rose by 4.6% from 2020 to 2023. Early screening and rapid diagnosis are essential elements of the World Health... Read more
AI Identifies Heart Valve Disease from Common Imaging Test
Tricuspid regurgitation is a condition where the heart's tricuspid valve does not close completely during contraction, leading to backward blood flow, which can result in heart failure. A new artificial... Read moreNuclear Medicine
view channel
Novel Radiolabeled Antibody Improves Diagnosis and Treatment of Solid Tumors
Interleukin-13 receptor α-2 (IL13Rα2) is a cell surface receptor commonly found in solid tumors such as glioblastoma, melanoma, and breast cancer. It is minimally expressed in normal tissues, making it... Read more
Novel PET Imaging Approach Offers Never-Before-Seen View of Neuroinflammation
COX-2, an enzyme that plays a key role in brain inflammation, can be significantly upregulated by inflammatory stimuli and neuroexcitation. Researchers suggest that COX-2 density in the brain could serve... Read moreGeneral/Advanced Imaging
view channel
CT-Based Deep Learning-Driven Tool to Enhance Liver Cancer Diagnosis
Medical imaging, such as computed tomography (CT) scans, plays a crucial role in oncology, offering essential data for cancer detection, treatment planning, and monitoring of response to therapies.... Read more
AI-Powered Imaging System Improves Lung Cancer Diagnosis
Given the need to detect lung cancer at earlier stages, there is an increasing need for a definitive diagnostic pathway for patients with suspicious pulmonary nodules. However, obtaining tissue samples... Read moreImaging IT
view channel
New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible
Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more